Breast Cancer Clinical Trials

414 studies are recruiting for breast cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Researching the Effect of Exercise on Cancer

   Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs and improves the body's use of oxygen) can reduce the level of ctDNA fo…

   Stage

   Not phased

   Ages

   18 and older

   Site

   City of Hope Medical Center, Durate, California

   Locations

   9 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT04589468 on ClinicalTrials.gov

2. MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

   Many people with cancer spend a lot of time and money traveling to and from the doctor's office for cancer care. MSK's goal is to make getting cancer care easier by cutting down the need to make in-person visits to MSK. MSK is trying to do this through a new option called enhanced telehealth.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06954337 on ClinicalTrials.gov

3. To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

   The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-c…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Los Angeles Cancer Network, Los Angeles, California

   Locations

   34 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT07368998 on ClinicalTrials.gov

4. A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

   A study to evaluate the efficacy and safety of triplet combination of inavolisib plus ribociclib and fulvestrant versus placebo plus ribociclib and fulvestrant in the first-line setting in participants with endocrine-therapy-resistant hormone receptor (HR)-positive (HR+), human epidermal growth fac…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Los Angeles Cancer Network - Anaheim, Anaheim, California

   Locations

   59 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT07405801 on ClinicalTrials.gov

5. A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

   This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   5 in total

   Run by

   Immunome, Inc.

   See if you can join NCT07578571 on ClinicalTrials.gov

6. Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

   Background: Breast cancer is the most common cancer among women. It can often spread to the liver, lungs, bones, or brain. Breast cancer that spreads to the brain is often fatal. Researchers want to know if tumor DNA found in spinal fluid, blood, or tumor tissue can help predict when the cancer wil…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07619534 on ClinicalTrials.gov

7. Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

   The purpose of this phase I study is to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of [177Lu]Lu-DWJ155 and the safety and imaging properties of [68Ga]Ga-DWJ155 in patients with histologically or cytologically confirmed advanced HER2+, HR+/HER2-negative, or tri…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   6 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT07660055 on ClinicalTrials.gov

8. Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

   This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Los Angeles, Los Angeles, California

   Locations

   6 in total

   Run by

   Regor Pharmaceuticals Inc.

   See if you can join NCT07524322 on ClinicalTrials.gov

9. Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

   Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs…

   Stage

   Phase 2

   Ages

   18 to 72

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03412877 on ClinicalTrials.gov

10. Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

    The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Northshore University Health System, Evanston, Illinois

    Locations

    7 in total

    Run by

    Carevive Systems, Inc.

    See if you can join NCT05974150 on ClinicalTrials.gov

11. Individuals on Hormone Therapy Breast Cancer Screening Pilot

    This investigation is a prospective breast cancer screening study open to all individuals on hormone therapy. Using a mixed methods approach, the study will 1) gather prospective quantitative breast imaging data in conjunction with hormone therapy and family cancer history and 2) investigate indivi…

    Stage

    Not phased

    Ages

    30 to 75

    Site

    Medical College of Wisconsin, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT06383026 on ClinicalTrials.gov

12. Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

    Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, researchers will modify th…

    Stage

    Phase 1

    Ages

    18 to 72

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT02830724 on ClinicalTrials.gov

13. Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer

    The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    New York-Presbyterian/Weill Cornell Medical Center, New York, New York

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT06072807 on ClinicalTrials.gov

14. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

    This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    St. Elizabeth Healthcare, Edgewood, Kentucky

    Locations

    17 in total

    Run by

    LigaChem Biosciences, Inc.

    See if you can join NCT06774963 on ClinicalTrials.gov

15. A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

    The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Oncology Institute, Long Beach, California

    Locations

    53 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT07102381 on ClinicalTrials.gov

16. A Study of Skipping Radiation Therapy in People With Breast Cancer

    The purpose of this study is to find out whether it is safe to skip (omit) radiation therapy to the breast after lumpectomy in people with low-risk HER2-positive breast cancer who are receiving HER2-targeted therapy.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (All protocol activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07895511 on ClinicalTrials.gov

17. Avera Cancer Sequencing and Analytics Protocol (ASAP)

    The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Avera Cancer Institute - Marshall, Marshall, Minnesota

    Locations

    6 in total

    Run by

    Avera McKennan Hospital & University Health Center

    See if you can join NCT05142033 on ClinicalTrials.gov

18. KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

    This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to tre…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Rutgers Cancer Institute, New Brunswick, New Jersey

    Locations

    2 in total

    Run by

    Christian Hinrichs

    See if you can join NCT05483491 on ClinicalTrials.gov

19. A Study of MGC026 in Participants With Advanced Solid Tumors

    The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalatio…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Angeles Clinic and Research Institute, Los Angeles, California

    Locations

    12 in total

    Run by

    MacroGenics

    See if you can join NCT06242470 on ClinicalTrials.gov

20. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

    This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    25 in total

    Run by

    Terremoto Biosciences Inc.

    See if you can join NCT07109726 on ClinicalTrials.gov

21. A Study of a Side Effects and Resource Navigation Program for People With Cancer

    The purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care. Investigators will also look at how the navigation program impacts participants' quality of life. Investigators will measure quality of life by having partici…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

    Locations

    8 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07646847 on ClinicalTrials.gov

22. A Study of 68Ga-FAPI Breast PET/MRI Scans in People With Breast Cancer

    The purpose of this study is to find out whether it is practical (feasible) to use a new type of imaging scan called 68Ga-FAPI PET/MRI (positron emission tomography/magnetic resonance imaging) to evaluate how well breast cancer responds to neoadjuvant chemotherapy.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    8 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07899892 on ClinicalTrials.gov

23. A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

    The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga …

    Stage

    Not phased

    Ages

    18 and older

    Site

    UC Davis EXPLORER Molecular Imaging Center, Sacramento, California

    Run by

    University of California, Davis

    See if you can join NCT05160480 on ClinicalTrials.gov

24. Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

    This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.

    Stage

    EARLY_Phase 1

    Ages

    18 to 99

    Site

    Stephenson Cancer Center, Oklahoma City, Oklahoma

    Locations

    2 in total

    Run by

    University of Oklahoma

    See if you can join NCT05921253 on ClinicalTrials.gov

25. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

    The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Katmai Oncology Group - Anchorage, Anchorage, Alaska

    Locations

    61 in total

    Run by

    Exact Sciences Corporation

    See if you can join NCT06401421 on ClinicalTrials.gov